NSE · APLLTD · Pharmaceuticals
Alembic Pharmaceuticals Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹1,868 Cr with net profit ₹197 Cr — a 10.54% net margin, versus 9.12% the period before.
Shareholding
As of 2026-06-30
- Promoter69.87%
- Public10.01%
- FII4.18%
- DII15.94%
86,796 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.57× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #22 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,43,013 Cr | 35.06 | 5.29 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,15,940 Cr | 23.74 | 4.27 | 18.59% | 16.09% |
| Cipla Ltd. | ₹1,11,816 Cr | 31.24 | 3.24 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,08,414 Cr | 99.14 | 20.44 | 16.77% | 15.04% |
| Mankind Pharma Limited | ₹1,02,435 Cr | 48.02 | 6.28 | 11.74% | 13.86% |
| Dr Reddys Laboratories Ltd. | ₹1,01,080 Cr | 31.37 | 2.66 | 11.07% | 9.73% |
| Aurobindo Pharma Ltd. | ₹97,814 Cr | 25.87 | 2.58 | 9.25% | 10.7% |
| Lupin Limited | ₹97,631 Cr | 16.39 | 4.32 | 23.76% | 18.72% |
| Glenmark Pharmaceuticals Ltd. | ₹69,467 Cr | 22.26 | 6.61 | 28.08% | 10.22% |
| Alkem Laboratories Ltd. | ₹63,746 Cr | 27.98 | 4.62 | 16.66% | 14.31% |
| Alembic Pharmaceuticals Ltd.(this company) | ₹16,514 Cr | 22.13 | 2.91 | 11.89% | 8.91% |
AI analysis
AI-generated · google/gemini-2.5-flashAlembic Pharmaceuticals Ltd. is listed with a market capitalization of Rs 16563 Cr. The company reported revenue of Rs 6714.63 Cr with a profit margin of 9.19%. Its PE ratio stands at 81.73 and its EPS is Rs 37.18. The stock's 52-week high is Rs 1038 and its 52-week low is Rs 635.8.
Positives
- +The debt-to-equity ratio is relatively low at 0.25.
- +Promoter holding is substantial at 69.8722% as of June 30, 2026.
- +No promoter shares are pledged.
Negatives
- −Quarterly EBITDA decreased from Rs 228.88 Cr in Dec 2025 to Rs 164.83 Cr in Mar 2026.
- −Annual EPS data is not available after Mar 2026 to evaluate recent year-on-year changes.
- −The number of shareholders decreased from 48284 in Dec 2017 to 42081 in Dec 2018.
Financial Performance
Alembic Pharmaceuticals Ltd. reported revenue of Rs 6714.63 Cr with a revenue growth rate of 7.1%. The company's profit margin for this period was 9.19%. For the quarter ending Mar 2026, revenue was Rs 1847.72 Cr with a net profit of Rs 202.7 Cr. Quarterly EBITDA for Dec 2025 was Rs 228.88 Cr, decreasing to Rs 164.83 Cr in Mar 2026.
Profitability & Returns
The company's profit margin is 9.19%. Return on equity (ROE) is 11.89%, and Return on Capital Employed (ROCE) is 10.81%. The earnings per share (EPS) is Rs 37.18. From Mar 2026, the EPS was Rs 34.33 on an annual basis. There is no annual EPS data available after Mar 2026 to assess recent trends.
Balance Sheet
Alembic Pharmaceuticals Ltd. maintains a debt-to-equity ratio of 0.25. The book value per share is Rs 288.7. The company's dividend yield is 143.
Ownership & Pledges
As of June 30, 2026, the promoter holding in Alembic Pharmaceuticals Ltd. is 69.8722%. Institutional holding stands at 20.1188%, comprising DII holding of 15.9396% and FII holding of 4.1792%. The public holds 10.009% of the shares. There are no pledged promoter shares.
Data as of — price: 2026-09-23 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Alembic Pharmaceuticals Ltd.share price & fundamentals